David Khayat

Professor Khayat is the founder and the President of the Foundation AVEC,[2] a non-profit organisation declared of public utility since 2013 (dissolved in 2020) .

He also became a consultant for various industries in the 2010s; in particular, he is paid by Philip Morris International for a lobbying activity in favor of heated tobacco product.

Over the next five years he undertook internship and residency training at hospitals in Paris, and moved towards the field of oncology.

In 1986, David Khayat went to the Mount Sinaï school medicine in New York (Department of Biochemistry, J.C Unkeless) and got his Ph.D. in tumor immunology in 1988 at the University Pierre and Marie Curie in Paris.

He demonstrated the relationship between the release of this soluble receptor in human serum (called also immunoglobuling binding factors IBF) and different pathologic conditions (AIDS, ITP ...).

Professor Khayat is the President of the Foundation AVEC,[5] a non-profit organisation which finances actions to improve the quality of life of cancer patients and research programmes.

He is also Adjunct Professor of Medicine of the Department of Breast Diseases at the MD Anderson Cancer Center, University of Texas, United States.

An investigation by Stéphane Horel and Jérémie Baruch for Le Monde relates that David Khayat, capitalizing on his worldly knowledge, undertook in the 2010s a consulting activity with industrialists on risk reduction.

In particular, he sought to influence public decisions in France (where senators indicate that they did not understand, at the time, that he was working for the tobacco company) and in Hong Kong.

Presently, he is employed at one of the few fully equipped research centers in France that is deeply involved in evaluation of new drugs and new targets for exploitation in treatment and diagnosis of cancer.